The importance of muscle glycogen as a fuel source during exercise has been well documented. Maintaining a high glycogen level before and during activity is a major determinant of performance. Elevation of glycogen levels during recovery from both aerobic and anaerobic bouts of exercise is critical. The purpose of this investigation was to determine the effect of a solid carbohydrate feeding on glycogen resynthesis following aerobic and anaerobic exercise. Eight male cyclists were recruited for this investigation. One hour ride trial, 70 % VO2max followed with feeding (HRY), one sprint trial followed with feeding (SPY), and one sprint trial followed with no feeding (SPN) were randomly performed and separated by ten days. Feeding trials consisted of a solid CHO source (1g CHO per kg bw per hr) fed for four hours of recovery following one hour of passive recovery with no food. Muscle biopsies were obtained immediate post and at six hours of recovery. Bloods were collected at 1, 4, and 30 minutes of recovery for lactate determination. Muscle specimens were analyzed for glycogen and lactate. Muscle glycogen (mmol • kg protein') levels post exercise for HRY, SPN, and SPY trial were 336.9±48.1, 481.0±47.0, and 417.5±26.4, respectively with HRY significantly lower than SPN. The increase in muscle glycogen six hours post-exercise for HRY, SPN, and SPY trials were 117.9±24.8, 29.5 ±22.2, and 207.2 ±20.4, respectively, which were all significantly different (P < 0.05). Blood lactate at + 1 minute for HRY, SPN, and SPY trials were 3.4±.5, 20.6±1.2, and 19.9±1.3 mM, respectively. These data suggest that an athlete training twice during the day with both anaerobic and aerobic components will have greater muscle glycogen available later in the day if anaerobic training is completed first in the day, providing adequate carbohydrate is consumed between bouts. / School of Physical Education

The structure of rabbit muscle glycogen phosphorylase b, an important regulatory enzyme in glycogen metabolism, has been studied by X-ray crystallographic techniques. This work was carried out as part of a group project, and the crystal structure of the enzyme had already been solved to 3 Å resolution, using the technique of Multiple Isomorphous Replacement. A search for additional heavy atom isomorphous derivatives was carried out, and photographic data to 3 Å resolution were collected for a further ethylmercurythiosalicylate derivative, using a screenless oscillation camera. The collection and reduction of this data, and the refinement of the heavy atom positions is described. The inclusion of this data allowed a new electron density map (with figure of merit = O.63) to be calculated, which enabled previously ambiguous areas in the electron density to be interpreted. Data to 2 Å resolution have been collected on an oscillation camera, using a synchrotron radiation source and cylindrical film cassettes. An intensity gain of up to 13O times, compared to a GX6 rotating anode source, was obtained with the synchrotron radiation source. A reduction in radiation damage, was also observed. The collection and reduction of the 2 Å data is described. The final overall merging R-factor was 15%. Some systematic errors remain in the data, and possible sources of these errors are discussed, and improvements to the data processing procedure suggested. The 2 Å data were empirically scaled to the 3 Å data and have been used in the first stages of the refinement of the phosphorylase b structure. The contribution of the crystallographic results towards an understanding of phosphorylase b as an allosteric protein is discussed.

A peritonite neutrofílica induzida por glicogênio acarreta antinocicepção em camundongos submetidos ao teste de contorção abdominal, a qual é mediada por uma proteína ligante de cálcio, com peso molecular de 14 kDa, denominada S100A9. O objetivo do presente trabalho foi aprofundar o estudo sobre o envolvimento dos neutrófilos na antinocicepção induzida pelo glicogênio em ratos submetidos ao teste de pressão de pata e avaliar a expressão da proteína S100A9 nos tempos onde foi detectado esse efeito. O glicogênio induz antinocicepção em ratos entre 2 e 12 horas após sua injeção intraplantar. O pré-tratamento dos animais com fucoidina, um inibidor de selectinas, não só reverte o efeito antinociceptivo observado como também induz hiperalgesia entre 2 e 6 horas após a injeção do glicogênio. Após 8 horas do tratamento com glicogênio, a fucoidina apenas inibiu a antinocicepção induzida pelo agente inflamatório. A análise histológica demonstrou um aumento na migração de células polimorfonucleares entre 2 e 8 horas após a administração de glicogênio, a qual foi inibida pelo pré-tratamento com fucoidina. Tanto a injeção subcutânea como intraplantar de naloxona, um inibidor inespecífico de receptores opioides, não interferiram no efeito antinociceptivo induzido pelo glicogênio, em nenhum dos tempos avaliados. Quanto à expressão da S100A9, analisada por &quot;Western Blotting&quot;, foi observado que as amostras obtidas do coxim plantar dos animais injetados com o glicogênio, entre 2 e 12 horas, apresentaram uma banda com peso molecular aproximado de 14 kDa, o qual equivale ao peso da proteína S100A9. A quantificação das bandas marcadas com o anticorpo anti-S100A9, nos tempos entre 2 e 12 horas, demonstrou um aumento significativo da expressão dessa proteína nas amostras obtidas dos animais tratados com glicogênio, em comparação com os tratados com salina. A injeção intraperitoneal de glicogênio induziu um aumento significativo no número total de células presentes na cavidade abdominal dos animais entre a 2&ordm; e a 12&ordm; hora após o tratamento, representado pelo aumento do número de células polimorfonucleares migradas. Os sobrenadantes obtidos do exsudato peritoneal entre 2 e 12 horas após a injeção de glicogênio, administrados via intraplantar, não só reverteram a hiperalgesia induzida pela carragenina (Cg) como induziram efeito antinociceptivo. Já, o sobrenadante obtido após 24 horas da injeção de glicogênio reverteu apenas parcialmente o efeito hiperalgésico induzido pela Cg. O tratamento do sobrenadante obtido 4 horas após a injeção do glicogênio com o anticorpo anti-S100A9 aboliu totalmente o efeito antinociceptivo observado com esse sobrenadante sobre a hiperalgesia induzida pela Cg. Esses dados sugerem que a antinocicepção acarretada pelo glicogênio em ratos submetidos ao modelo de pressão de pata é dependente da migração neutrofílica, não está relacionado à liberação de peptídeos opioides, mas possivelmente à secreção da proteína S100A9 por essas células. Ainda, os resultados obtidos com os sobrenadantes do exsudato peritoneal após a injeção do glicogênio, demonstram que durante a peritonite neutrofílica é secretada uma molécula capaz tanto de inibir a hiperalgesia acarretada pela carragenina quanto induzir antinocicepção, a qual possivelmente é a proteína S100A9. / Neutrophilic peritonitis induced by glycogen causes antinociception in mice subjected to the writhing test, which is médiated by a calcium-binding protein with a molecular mass of 14 kDa, named S100A9. The purpose of this study was to deepen the study on the involvement of neutrophils in glycogen-induced antinociception in rats subjected to the paw pressure test and evaluate the expression of S100A9 protein in time periods when this effect was detected. Glycogen induces antinociception in rats between 2 and 12 hours after intraplantar injection. Pretreatment of animals with fucoidan, a selectin inhibitor, not only reversed the antinociceptive effect, but also induces hyperalgesia between 2 and 6 hours after glycogen injection. Eight hours after treatment with glycogen, fucoidan only inhibited the antinociception induced by the inflammatory agent. Histological analysis showed an increased migration of polymorphonuclear cells between 2 and 8 hours after glycogen administration, which was inhibited by pretreatment with fucoidan. Both intraplantar and subcutaneous injection of naloxone, a nonspecific inhibitor of opioid receptors, did not affect the antinociceptive effect induced by glycogen at all evaluated times. In relation to the expression of S100A9 analyzed by Western blotting, it was observed that the samples obtained from the footpad injected with glycogen, between 2 and 12 hours, had a band with a molecular weight of 14 kDa, which is similar to molecular weight of S100A9. Relative quantification of the bands marked with anti-S100A9 in the time periods between 2 and 12 hours showed a significant increase in protein expression in samples obtained from animals treated with glycogen, compared with those treated with saline. Intraperitoneal injection of glycogen induced a significant increase in the total number of cells in the abdominal cavity of animals between 2 and 12 hours after treatment, represented by increased numbers of migrated polymorphonuclear cells. The supernatants obtained from peritoneal exudate between 2 and 12 hours after injection of glycogen, administered intraplantarly, not only reversed the hyperalgesia induced by carrageenan (Cg) but also induced antinociceptive effect. Already, the supernatant obtained 24 hours after injection of glycogen only partially reversed the hyperalgesic effect induced by Cg. The treatment of the supernatant obtained 4 hours after injection of glycogen with anti-S100A9 abolished the antinociceptive effect observed with the supernatant on hyperalgesia induced by Cg. These data suggest that antinociception entailed by glycogen in rats submitted to the paw pressure is dependent on neutrophil migration. Moreover, this effect is not related to the release of opioid peptides but possibly to the S100A9 protein secretion by these cells. In addition, the results obtained with the supernatants of peritoneal exudate after glycogen injection show that during neutrophilic peritonitis a molecule able to inhibit carrageenan-induced hyperalgesia is secreted and induce antinociception entailed by glycogen, which is possibly the S100A9 protein.

Orientador: Alexandre Secorun Borges / Coorientador: José Paes de Oliveira Filho / Banca: João Pessoa Araújo Júnior / Banca: Luiz Cláudio Nogueira Mendes / Resumo: A Deficiência da Enzima Ramificadora de Glicogênio (Glycogen Branching Enzyme Deficiency [GBED] em equinos é uma doença hereditária recessiva fatal, caracterizada principalmente por abortos, natimortos e nascimento de potros fracos. A GBED é causada por uma mutação no gene GBE1. Não existem dados acerca da existência de animais com esta mutação no Brasil. O objetivo deste estudo foi verificar a prevalência de animais portadores do alelo mutante da GBED em cavalos da raça Quarto de Milha utilizados em cinco modalidades esportivas equestres no Brasil. Amostras de sangue e pêlo foram obtidas de 740 animais. Após purificação do DNA, foram realizados as reações de PCR, sequenciamento direto automatizado e análise das sequências. Dos 740 animais testados 59 foram considerados heterozigotos para a mutação responsável pela GBED representando uma frequência de 7,97% na população estudada. As prevalências de heterozigotos foram maiores nas linhagens de apartação (20%) e rédeas (10%), seguidos por tambor/baliza (5%) e conformação (3%), não foram encontrados heterozigotos para a modalidade de corrida. Os resultados demostram que a mutação está presente no rebanho brasileiro de cavalos Quarto de milha, e sugere que a doença (homozigotos recessivos) pode estar presente de forma silenciosa. Portanto a GBED deve ser considerada no diagnóstico diferencial nos casos de abortos e morte neonatal em cavalos da raça Quarto de milha no Brasil, e medidas de prevenção da transmissão da mutação devem ser estabelecidas / Abstract: The deficiency of glycogen branching enzyme [GBED] in horses is a fatal recessive hereditary disease, mainly characterized by abortions, stillbirths and birth of weak foals. The GBED is caused by a mutation in the gene GBE1. The aim of this study was to determine the prevalence of mutation carriers causing GBED in a population of Quarter horse animals used in five equestrian sports practiced in Brazil. Samples of blood and were obtained from 740 animals. After DNA purification, PCR reactions, automated direct sequencing and sequence analysis were performed. Of the 740 animals tested 59 were considered heterozygous for the mutation responsible for GBED representing a prevalence of 7.97% in the population studied. The prevalences of heterozygotes were higher in cutting (20%) and reining (10%) subgroups, followed by barrel racing (5%) and halter (3%), were not found heterozygous for the racing subgroup. The results demonstrate that the mutation is present in the Quarter horse Brazilian herd, and suggests that the disease (homozygous recessive) may be present without being noticed. So the GBED should be considered in the differential diagnosis in cases of abortion and stillbirths in Brazilian Quarter horses and strategies should be developed to prevent transmission of the mutation / Mestre

A peritonite neutrofílica induzida por glicogênio acarreta antinocicepção em camundongos submetidos ao teste de contorção abdominal, a qual é mediada por uma proteína ligante de cálcio, com peso molecular de 14 kDa, denominada S100A9. O objetivo do presente trabalho foi aprofundar o estudo sobre o envolvimento dos neutrófilos na antinocicepção induzida pelo glicogênio em ratos submetidos ao teste de pressão de pata e avaliar a expressão da proteína S100A9 nos tempos onde foi detectado esse efeito. O glicogênio induz antinocicepção em ratos entre 2 e 12 horas após sua injeção intraplantar. O pré-tratamento dos animais com fucoidina, um inibidor de selectinas, não só reverte o efeito antinociceptivo observado como também induz hiperalgesia entre 2 e 6 horas após a injeção do glicogênio. Após 8 horas do tratamento com glicogênio, a fucoidina apenas inibiu a antinocicepção induzida pelo agente inflamatório. A análise histológica demonstrou um aumento na migração de células polimorfonucleares entre 2 e 8 horas após a administração de glicogênio, a qual foi inibida pelo pré-tratamento com fucoidina. Tanto a injeção subcutânea como intraplantar de naloxona, um inibidor inespecífico de receptores opioides, não interferiram no efeito antinociceptivo induzido pelo glicogênio, em nenhum dos tempos avaliados. Quanto à expressão da S100A9, analisada por &quot;Western Blotting&quot;, foi observado que as amostras obtidas do coxim plantar dos animais injetados com o glicogênio, entre 2 e 12 horas, apresentaram uma banda com peso molecular aproximado de 14 kDa, o qual equivale ao peso da proteína S100A9. A quantificação das bandas marcadas com o anticorpo anti-S100A9, nos tempos entre 2 e 12 horas, demonstrou um aumento significativo da expressão dessa proteína nas amostras obtidas dos animais tratados com glicogênio, em comparação com os tratados com salina. A injeção intraperitoneal de glicogênio induziu um aumento significativo no número total de células presentes na cavidade abdominal dos animais entre a 2&ordm; e a 12&ordm; hora após o tratamento, representado pelo aumento do número de células polimorfonucleares migradas. Os sobrenadantes obtidos do exsudato peritoneal entre 2 e 12 horas após a injeção de glicogênio, administrados via intraplantar, não só reverteram a hiperalgesia induzida pela carragenina (Cg) como induziram efeito antinociceptivo. Já, o sobrenadante obtido após 24 horas da injeção de glicogênio reverteu apenas parcialmente o efeito hiperalgésico induzido pela Cg. O tratamento do sobrenadante obtido 4 horas após a injeção do glicogênio com o anticorpo anti-S100A9 aboliu totalmente o efeito antinociceptivo observado com esse sobrenadante sobre a hiperalgesia induzida pela Cg. Esses dados sugerem que a antinocicepção acarretada pelo glicogênio em ratos submetidos ao modelo de pressão de pata é dependente da migração neutrofílica, não está relacionado à liberação de peptídeos opioides, mas possivelmente à secreção da proteína S100A9 por essas células. Ainda, os resultados obtidos com os sobrenadantes do exsudato peritoneal após a injeção do glicogênio, demonstram que durante a peritonite neutrofílica é secretada uma molécula capaz tanto de inibir a hiperalgesia acarretada pela carragenina quanto induzir antinocicepção, a qual possivelmente é a proteína S100A9. / Neutrophilic peritonitis induced by glycogen causes antinociception in mice subjected to the writhing test, which is médiated by a calcium-binding protein with a molecular mass of 14 kDa, named S100A9. The purpose of this study was to deepen the study on the involvement of neutrophils in glycogen-induced antinociception in rats subjected to the paw pressure test and evaluate the expression of S100A9 protein in time periods when this effect was detected. Glycogen induces antinociception in rats between 2 and 12 hours after intraplantar injection. Pretreatment of animals with fucoidan, a selectin inhibitor, not only reversed the antinociceptive effect, but also induces hyperalgesia between 2 and 6 hours after glycogen injection. Eight hours after treatment with glycogen, fucoidan only inhibited the antinociception induced by the inflammatory agent. Histological analysis showed an increased migration of polymorphonuclear cells between 2 and 8 hours after glycogen administration, which was inhibited by pretreatment with fucoidan. Both intraplantar and subcutaneous injection of naloxone, a nonspecific inhibitor of opioid receptors, did not affect the antinociceptive effect induced by glycogen at all evaluated times. In relation to the expression of S100A9 analyzed by Western blotting, it was observed that the samples obtained from the footpad injected with glycogen, between 2 and 12 hours, had a band with a molecular weight of 14 kDa, which is similar to molecular weight of S100A9. Relative quantification of the bands marked with anti-S100A9 in the time periods between 2 and 12 hours showed a significant increase in protein expression in samples obtained from animals treated with glycogen, compared with those treated with saline. Intraperitoneal injection of glycogen induced a significant increase in the total number of cells in the abdominal cavity of animals between 2 and 12 hours after treatment, represented by increased numbers of migrated polymorphonuclear cells. The supernatants obtained from peritoneal exudate between 2 and 12 hours after injection of glycogen, administered intraplantarly, not only reversed the hyperalgesia induced by carrageenan (Cg) but also induced antinociceptive effect. Already, the supernatant obtained 24 hours after injection of glycogen only partially reversed the hyperalgesic effect induced by Cg. The treatment of the supernatant obtained 4 hours after injection of glycogen with anti-S100A9 abolished the antinociceptive effect observed with the supernatant on hyperalgesia induced by Cg. These data suggest that antinociception entailed by glycogen in rats submitted to the paw pressure is dependent on neutrophil migration. Moreover, this effect is not related to the release of opioid peptides but possibly to the S100A9 protein secretion by these cells. In addition, the results obtained with the supernatants of peritoneal exudate after glycogen injection show that during neutrophilic peritonitis a molecule able to inhibit carrageenan-induced hyperalgesia is secreted and induce antinociception entailed by glycogen, which is possibly the S100A9 protein.

L’objectif de notre étude est de comprendre les mécanismes impliqués dans la variation des qualités sensorielles et technologiques de la viande de porc. Les différentes expérimentations nous ont permis de mettre en évidence le rôle de l’oxydation des protéines dans la variation de qualités des viandes. Les modifications structurales qui ont en découlé participent également à l’élucidation des mécanismes à l’origine de la diminution du pouvoir en rétention d’eau. L’application des traitements thermiques sur la viande accentue les phénomènes oxydatifs dans lesquels la myosine et de l’actine sont des cibles privilégiées, impliquées dans la formation d’agrégats protéiques. Enfin, le rôle du glycogène comme potentialisateur de l’oxydation protéique a été démontré. / We aimed to better understand the mechanisms underlying sensorial and technological meat qualities. The experimental design put into relief the important role of protein oxidation in meat quality. As a consequence of oxidation, structural changes of proteins demonstrated also their implication in water holding capacity. Heating enhanced the oxidative process in which myosin and actin can be considered as favoured protein target. Moreover these proteins are implicated in aggregation /polymerization. Finally, glycogen as a catalyst of protein oxidation was demonstrated.

Glycogen levels were studied in 15 Sprague-Dawley adult male rats. Three aspects of glycogen metabolism were considered. First, the glycogen concentrations of normally innervated red (soleus) and white (gastrocnemius) muscles were compared. Second, the glycogen content of innervated red and white muscles were compared to chronically denervated red and white muscles. Third, the effect of insulin upon glycogen stores in innervated and chronically denervated red and white muscles was examined.Innervated white muscles had higher glycogen levels than innervated red muscles. However, chronic denervation resulted in statistically significant decreases in red and white muscle glycogen content. In addition, insulin markedly increased glycogen stores in innervated red muscles, but not in white muscles. Further, the increase in glycogen levels in red muscle caused by insulin was abolished in chronically denervated preparations.The results suggest that the effects of insulin on skeletal muscle glycogen stores could be related to trophic influences of motor nerves.Ball State UniversityMuncie, IN 47306

Previous investigations have utilized extremes of diet and exercise during the week prior to a performance to raise muscle glycogen levels to 220 mmoles/kg wet tissue. This investigation was designed to determine if muscle glycogen levels can be supercompensated utilizing a combination of a depletion-taper sequence and diets of 15% carbohydrate (CHO, LC), 50% CHO (M), and 70% CHO (HC) in 3,000 kcal. Each depletion-taper sequence was conducted on a treadmill at 73% V02max and consisted of runs of 90, 40, 40, 20, 20 minutes and a day of rest on the six days prior to a 13 mile performance run. Trial C consisted of 3 days LC and 3 days HC; Trial B, consisted of 3 days M and 3 days HC; and Trial C, 6 days M. Muscle biopsies were obtained from the gastrocnemius prior to loading (day 4) and before and after the performance run. Trials A, B and C elevated muscle glycogen to 207, 203 and 160 mmoles/ kg wet tissue, respectively. Trials A and B resulted in significantly more glycogen utilization (105 and 107 mmoles/kg wet tissue, respectively) than did Trial C (65 mmoles/kg wet tissue). The times during the performance runs were not significantly different between the Trials. It is concluded that: 1. muscle glycogen levels can be supercompensated to levels comparable to previous investigations by employing a depletion-tapering sequence and less severe alteration in diet prior to competition; 2. carbohydrate loading is not necessary for trained runners preparing for a race of 13 miles.Supported by the National Dairy Council and the Ball State University Graduate Student Research Fund, 1980.Ball State UniversityMuncie, IN 47306

<p>Selective therapeutic targeting of tumors requires identification of differences between the homeostatic requirements of cancer and host cells. One such difference is the manner in which cancer cells acquire energy. Cancer cells often grow in an environment of local hypoxia; under these conditions tumor cells depend on glycolysis for energy, but are unable to perform oxidative phosphorylation. Many tumor cells, despite normoxic conditions, continue to perform glycolysis without oxidative phosphorylation. The net result of glycolysis without oxidative phosphorylation is twofold: the need to consume a greater amount of glucose than a non-cancerous host cell, and the burden of increased intracellular lactic acid. The proteins responsible for the transport of lactic acid in and out of cells are known as the monocarboxylate transporters (MCTs). Monocarboxylate Transporter 1 (MCT1) and Monocarboxylate Transporter 4 (MCT4) are the MCTs that play a major role in the transport of lactic acid. Tumor cells depend on MCT1 and MCT4 activity to excrete excess intracellular lactic acid to maintain neutral intracellular pH and homeostasis. Using human neuroblastoma and prostate cancer cell lines this work demonstrates that tumor cells can be selectively targeted tumor under conditions of hypoxia or acidosis in vitro with the drug lonidamine, with a small molecule inhibitor selective for MCT1, or with RNA interference of MCT1. Inhibition of MCT1 activity in neuroblastoma cells under acidic extracellular conditions results in intracellular acidification and cell death. MCT1 mRNA is expressed in human neuroblastoma and positively correlated with clinical risk profile. Inhibition of MCT1 activity in hypoxic prostate cancer cells results in a reduction of lactate excretion, decreased intracellular pH, inhibition of ATP production, and subsequent cell death. MCT1 expression in sections of human prostate tumors has been demonstrated to validate MCT1 as a target in prostate cancer.</p> <p>Through the Pasteur and Warburg effects, tumors have an increased demand for glucose. Some cancers store glycogen, but the reasons for this are largely unknown. It is hypothesized that tumor glycogen is used to promote tumor survival during transient hypoxia or low glucose, and that the mechanisms by which glycogen is stored is a potential therapeutic target in cancer. Tumors from human cell lines (WiDr, PC3, FaDu) have been grown in nude mice, sectioned and stained to measure glycogen storage. Using consecutive frozen sections, levels of hypoxia, glucose, lactate, ATP, and CD31, an endothelial cell marker, have been determined. These sections have been employed to elucidate the "architecture" of tumor metabolism in terms of vessel distance. Additionally, PAS-stained EF5 labeled human tumor samples were used to obtain calibrated hypoxia measurements to correlate with PAS. These studies demonstrate a correlation between hypoxia and the formation of glycogen deposits in human tumors and nude mouse xenografts. In cell culture, formation of glycogen deposits after exposure to hypoxia has been demonstrated, in addition to expression of glycogen synthase in human cancer cell lines.</p> <p>The development of novel selective cancer chemotherapeutics will require the identification of differences between cancerous cells and normal host cells to exploit as targets. Several differences in metabolism, including the need to excrete excess lactic acid and store glycogen under hypoxic conditions, are such targets. Novel therapeutics exploiting these targets should be effective against cancer cells and minimally toxic to host cells.</p> / Dissertation

Thesis (Ph. D.)--University of Washington, 2003. / Vita. Includes bibliographical references (leaves 91-98).